Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity

Sialic acid-binding Immunoglobulin-like lectin-9 (Siglec-9) is a glyco-immune negative checkpoint expressed on several immune cells. Siglec-9 exerts its inhibitory effects by binding to sialoglycan ligands expressed on cancer cells, enabling them to evade immunosurveillance. We developed a panel of...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hyeree, Ho, Michelle, Adeniji, Opeyemi S., Giron, Leila, Bordoloi, Devivasha, Kulkarni, Abhijeet J., Puchalt, Alfredo Perales, Abdel-Mohsen, Mohamed, Muthumani, Kar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640189/
https://www.ncbi.nlm.nih.gov/pubmed/34869028
http://dx.doi.org/10.3389/fonc.2021.778989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640189/
https://www.ncbi.nlm.nih.gov/pubmed/34869028
http://dx.doi.org/10.3389/fonc.2021.778989

Ejemplares similares